Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
You could win a cash prize of up to £25,000 when you play the JDRF lottery. As well as the chance to win great prizes, you'll also help fund our research to find a cure for type 1 diabetes.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join us on Saturday 21 September 2024 with hundreds of JDRF supporters celebrating One Walk Belfast!
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF is undergoing a transformation.We are becoming Breakthrough T1D in October.
Home > Knowledge & support > Resource hub > Type 1 diabetes research at the University of Birmingham
We were delighted to be invited to the University of Birmingham to meet some of our fantastic JDRF-funded researchers. They shared exciting research updates and took us behind the scenes of the UK’s biggest screening study for type 1 diabetes.
The first stop on our tour was the Queen Elizabeth Medical Centre, where Professor Parth Narendran introduced us to the team running The ELSA Study. The team are screening 20,000 children aged 3-13 across the UK for type 1. This will provide insights into practical and effective ways to screen the UK population. Screening for type 1 is crucial to find people who may benefit from immune therapies and to educate people of the signs of type 1 to prevent diagnosis in diabetic ketoacidosis.
We followed the blood testing kits from the packing and posting stage right through to Professor Alex Richter’s JDRF-funded lab, where researcher Chris analyses the blood samples. He is looking for specific proteins that attack insulin-producing cells and mean someone is at risk of developing type 1. Children in the study currently do a finger prick and send blood spots back to the lab. Alex is improving this process by developing a lateral flow test, like COVID-19 tests, which reveal the result within 15 minutes. This will provide almost immediate reassurance for the 99% of children who test negative for type 1.
In summer 2023, paramedics and nurses from the South Central Ambulance Service joined the ELSA Study team, screening children in GP practices, schools and community centres. In October, the research team expanded the project to include children in Northern Ireland, meaning children in all four UK nations can take part. Over 10,000 families have now enrolled in the ELSA study across the UK!
Three of the JDRF-funded researchers who raised money for JDRF Alex, Parth and Lauren.
Four researchers from The ELSA Study took part in our Tri for Type 1: Swim challenge this August, where they swam a combined distance of 21 miles – the length of the English Channel!
Clinical Research Fellow, Dr Lauren Quinn, said: “I’m really proud to be raising money for JDRF because of all the work they do to support people living with diabetes; the people diagnosed with type 1, their family, parents, carers and young people. A huge thank you to everyone living with type 1 and all the work JDRF does to support them!”
Thanks to an incredible £1m donation from the Steve Morgan Foundation, Professor Timothy Barrett is running a clinical trial of semaglutide in hospitals across England. Semaglutide can reduce blood sugar levels by increasing the amount of insulin released, stopping glucagon release, and slowing stomach emptying. You may have heard of the drug under the brand name Ozempic.
The drug is already licensed to treat type 2 diabetes in the UK. Now, Tim is investigating whether it could help treat type 1. Tim told us that his clinical trial, known as ‘The SMILE Trial’, will begin in January 2024 involving 240 young people with type 1 aged 10-24 years. His team will give 144 of participants an injection of semaglutide each week for 36 weeks and the remaining group a non-active placebo, plus their usual insulin treatment.
Tim will compare the blood sugar of the young people in each group to determine how semaglutide affects glucose levels. He hopes the results will show that semaglutide can help young people manage their type 1.
The last researcher we met was Professor David Wraith, a veteran of autoimmune research with 35 years of immunology research under his belt. Autoimmunity is where our immune system attacks our own body cells instead of harmful invaders like bacteria and viruses. Type 1 diabetes, multiple sclerosis (MS), and rheumatoid arthritis are all examples of autoimmune conditions.
With his experience in multiple autoimmune conditions, David was instrumental in setting up our Connect Immune Research partnership. The partnership of 11 autoimmune research organisations aims to accelerate the progression and impact of autoimmune research by funding projects investigating the underlying biology of autoimmunity.
David is currently working on a new way to treat autoimmune conditions using tiny proteins called peptides. The peptides can switch the immune cells responsible for autoimmunity from their destructive state into their protective state. This causes other immune cells to switch to their protective state too, stopping the autoimmune attack on body cells, such as the insulin-producing cells targeted in type 1.
David has run clinical trials of these peptides in people with MS and tests in animals with type 1. He will now test whether the peptides are safe and effective in a small number of people newly diagnosed with type 1. Encouragingly peptides are very cheap compared to other drugs like immune therapies, so could hopefully become an affordable and accessible treatment to prevent type 1 in the future.
Changing our name to Breakthrough T1D marks a pivotal moment in our journey to transform the future of type 1 diabetes (T1D). Terence Lovell, Fundraising & Engagement Director at JDRF explores how we can work together as one community to make change happen.
The ELSA Study is a research project, co-funded by JDRF, screening children aged 3-13 years in the UK for early signs of type 1 diabetes. The research team has joined forces with Birmingham Community Healthcare NHS Trust (BCHC) to reach communities that are often underrepresented in research.
Our CEO, Karen Addington, talks through the history and evolution of our new brand, Breakthrough T1D.
Tom Gordon, our Senior Policy and Public Affairs Officer, talks about how and why we're highlighting mental health and type 1 at the highest levels of government.
Our research is improving the lives of people with type 1 and making strides towards a cure. We’ll keep pushing until we make type 1 diabetes a thing of the past.
Please note that your consent will be valid across all our subdomains. You can change or withdraw your consent at any time by clicking the “Consent Preferences” button at the bottom of your screen. We respect your choices and are committed to providing you with a transparent and secure browsing experience.
